Novo Nordisk is facing a massive wave of generic competitors to its injectable formulations of GLP-1 agonist semaglutide, used to treat diabetes and obesity, as a key patent in India is due to expire ...

NEW DELHI: With prices of GLP-1 drugs crashing and their generic versions flooding the market, govt has cracked down on their misuse, inspecting 49 businesses and issuing notices while also flagging ...

March 31 (Reuters) - Danish drugmaker Novo Nordisk on Tuesday further slashed the price of its popular diabetes and weight-loss drugs Ozempic and Wegovy by as much as 36% and 48% in India to better ...

TORONTO - Anne Welch worked a physically demanding job at her local SPCA — lifting pets, cleaning kennels and walking dogs — until she retired at age 71. With the loss of that physical activity, ...

The FDA has approved the first generic versions of Farxiga, a drug used to treat Type 2 diabetes and reduce the risk of hospitalization for heart failure. The generic, dapagliflozin, is indicated to ...

Eli Lilly's market share in India's weight‑loss drug market fell to 56% in March from 61% in February. Novo Nordisk's market share remained steady at 25%. Indian generic drugmakers have launched 26 ...

In a groundbreaking move, Novo Nordisk has slashed prices on its renowned diabetes and weight-management medications, Ozempic and Wegovy, in India. This strategic decision comes in the wake of local ...

March 31 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab has again cut the prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 36% and 48% in India, to fend off ...

Novo Nordisk AS has slashed prices of its blockbuster weight-loss drugs Ozempic and Wegovy in India, amid an onslaught of copycat drugs in the world's third most overweight population. Many patients ...

The Indian Pharmaceutical Market (IPM) clocked a robust double-digit value growth of 10.1 per cent in March 2026, primarily powered by a seismic shift in the anti-diabetic segment. Latest data from ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...